Every material Form 8-K Solventum filed with the SEC in 2026, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
Solventum reported third-quarter 2026 net sales of $1.9 billion, a 7.0 percent decrease on a reported basis due to prior-quarter advance orders placed ahead of ERP cutovers. Despite the sales decline and a GAAP net loss of $12 million, the company raised its full-year adjusted diluted EPS guidance to a range of $7.20 to $7.30 and expects organic sales growth toward the high end of its +2.5% to +3.0% range.
Q3 2026 net sales were $1.9 billion, reflecting a 7.0% reported decrease and a 2.8% organic decrease.
GAAP diluted earnings per share was $(0.07), while adjusted diluted earnings per share was $1.45.
Full-year adjusted EPS guidance was raised to $7.20 to $7.30 from the prior range of $7.10 to $7.20.
Solventum reported second-quarter 2026 net sales of $2.2 billion, up 2.2% reported and 9.5% organic, with GAAP diluted EPS of $0.53 and adjusted diluted EPS of $2.55. The company raised its full-year 2026 guidance for organic sales growth, adjusted EPS and free cash flow, and announced its intent to separate the Health Information Systems segment. GAAP results were weaker in some areas, including a GAAP operating margin of 8.2% versus 9.9% a year earlier.
Q2 net sales of $2.2 billion, up 2.2% reported and 9.5% organic; GAAP diluted EPS $0.53 vs. $0.51 a year earlier
Adjusted diluted EPS of $2.55 vs. $1.69 in Q2 2025, a 50.9% increase
2026 adjusted EPS guidance raised to $7.10 to $7.20, from the upper end of the prior $6.40 to $6.60 range
Intent to separate Health Information Systems segment; six-month net income was $105 million, down 53.7%
Solventum appointed Neil Zieselman as Senior Vice President, Controller and Chief Accounting Officer, effective August 10, 2026, replacing Mary Wilcox, who is retiring. He will also serve as principal accounting officer for SEC reporting and report to CFO Wayde McMillan. The filing describes the change as a planned succession in a key finance role, with no financial results disclosed.
Neil Zieselman, age 50, previously served as Senior Vice President, Corporate Finance and Controller at Surgery Partners, Inc. since May 2022
Compensation includes a 50% target annual bonus, a $500,000 long-term incentive target award and a $130,000 cash sign-on bonus
Initial grant of $600,000 in restricted stock units vests in three equal installments over three years
Board appointed him on July 16, 2026, in connection with Mary Wilcox's previously announced retirement
Solventum's Talent Committee approved a new Executive Severance Plan on May 21, 2026, effective June 1, 2026, replacing the prior plan from April 1, 2024. The filing says the new plan changes severance terms for executives, including a lump-sum COBRA payment for the CEO and direct reports, and provides for forfeiture of certain post-effective date equity awards.
Plan adopted May 21, 2026 by the Talent Committee of the Board, effective June 1, 2026, replacing the Prior Plan effective April 1, 2024
CEO direct reports generally receive 12 months of base salary plus prorated incentive pay; executives eligible for 18 months keep that amount for two years
CEO and direct reports receive a lump-sum payment equal to COBRA premiums for the severance period
Solventum reported first-quarter 2026 results on May 5, 2026, with net sales down 3.0% to $2.0 billion on a reported basis and up 2.1% on an organic basis. GAAP diluted EPS fell to $0.07 from $0.78, while adjusted diluted EPS rose 10.6% to $1.48. The company affirmed its full-year 2026 organic sales growth and free cash flow guidance and said adjusted EPS is estimated to be toward the high end of its $6.40 to $6.60 range.
Reported sales of $2.0 billion, down 3.0% from $2.07 billion a year earlier; organic sales up 2.1%
GAAP net income of $13 million versus $137 million, with separation and restructuring costs weighing on results
Adjusted diluted EPS of $1.48 versus $1.34; free cash flow was negative $273 million
Full-year 2026 guidance affirmed, with free cash flow of about $200 million and adjusted EPS toward the high end of $6.40 to $6.60
Solventum Corporation disclosed that Mary Wilcox informed the company on March 20, 2026 of her intent to retire and resign as Chief Accounting Officer, pending the search for and appointment of a successor. The filing is a routine leadership transition for a senior finance role and does not report any financial results or guidance changes.
Mary Wilcox notified Solventum of her intent to retire and resign as Chief Accounting Officer on March 20, 2026.
Her departure is contingent on the company appointing a successor following a search.
The filing does not name a successor or state an effective departure date.
The 8-K was signed by CFO Wayde McMillan on March 24, 2026.
Solventum reported fourth-quarter 2025 net sales of $1,998 million, down 3.7% on a reported basis but up 3.5% organically, and introduced 2026 full-year guidance. Adjusted diluted EPS rose to $1.57 from $1.41, while the company guided to 2026 adjusted EPS of $6.40 to $6.60, compared with $6.11 for full-year 2025.
Q4 2025 reported net sales of $1,998 million, down 3.7%; organic sales up 3.5%
Q4 2025 GAAP diluted EPS of $0.36 versus $0.17; adjusted diluted EPS of $1.57 versus $1.41
2026 guidance: organic sales growth of 2.0% to 3.0%, adjusted EPS of $6.40 to $6.60, and free cash flow of about $200 million
Full-year 2025 free cash flow was negative $10 million and adjusted EPS was $6.11, down 8.8%
Briefs are written by AI from the filing text (each brief's own page names the model) and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the model's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every Solventum filing is on SEC EDGAR ↗. 8-K briefs of other companies →